Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)

被引：0
|
作者：
Chugh, R. [1 ]
Kummar, S. [2 ]
Schneider, R. E. [3 ]
Janik, T. [4 ]
Manamley, N. [5 ]
Hilgier, K. [4 ]
Strauss, J. [3 ]
机构：
[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[2] OHSU Knight Canc Inst, Div Hematol & Med Oncol, Ctr Hlth & Healing, Bldg 1 South Waterfront, Portland, OR USA
[3] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA
[4] Mundipharma Res Ltd, Clin Dev Oncol & Hematol, Cambridge, England
[5] Mundipharma Int, R&D, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1186
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1957P
引用
收藏
页码：S1048 / S1048
页数：1
相关论文
共 50 条
  • [41] Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis
    Ebi, N.
    Semba, H.
    Tokunaga, S.
    Takayama, K.
    Wataya, H.
    Kuraki, T.
    Yamamoto, H.
    Akamine, S.
    Okamoto, I.
    Nakanishi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
    Gordon, M. S.
    Vogelzang, N. J.
    Schoffski, P.
    Daud, A.
    Spira, A. I.
    O'Keeffe, B. A.
    Rafferty, T.
    Lee, Y.
    Berger, R.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
    Kotecki, N.
    Le Cesne, A.
    Tresch-Bruneel, E.
    Mir, O.
    Chevreau, C.
    Bertucci, F.
    Delcambre, C.
    Saada-Bouzid, E.
    Piperno-Neumann, S.
    Bay, J-O.
    Ray-Coquard, L.
    Ryckewaert, T.
    Isambert, N.
    Italiano, A.
    Clisant, S.
    Blay, J-Y.
    Penel, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] PAZOPANIB (GW786034) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY SOFT TISSUE SARCOMA (STS); A PHASE II STUDY FROM THE EORTC STBSG (EORTC 62043)
    Sleijfer, S.
    Ray-Coquard, I.
    Papai, Z.
    Le Cesne, A.
    Schoeffski, P.
    Collin, F.
    Pandite, L.
    Marreaud, S.
    De brauwer, A.
    Blay, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 267 - 267
  • [45] IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.
    Palmerini, Emanuela
    Lopez-Pousa, Antonio
    Grignani, Giovanni
    Redondo, Andres
    Hindi, Nadia
    Stacchiotti, Silvia
    Sebio, Ana
    Lopez-Martin, Jose A.
    Morales, Claudia Maria Valverde
    Martinez-Trufero, Javier
    Gutierrez, Antonio
    de Alava, Enrique
    D'Ambrosio, Lorenzo
    Collini, Paola
    Picci, Piero
    Casali, Paolo Giovanni
    Broto, Javier Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Hollebecque, Antoine
    Gazzah, Anas
    Bahleda, Rastislav
    Menis, Jessica
    Champiat, Stephane
    El-Dakdouki, Yolla
    Paoletti, Xavier
    Ribrag, Vincent
    Michot, Jean-Marie
    Rafie, Saloomeh
    Planchard, David
    Besse, Benjamin
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Besse, Benjamin
    Planchard, David
    Champiat, Stephane
    Angevin, Eroc
    Hollebecque, Antoine
    Bahleda, Rastislav
    Gazzah, Anas
    Armand, Jean-Pierre
    Paoletti, Xavier
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.
    Javle, Milind M.
    Mahipal, Amit
    Fonkoua, Lionel Aurelien Kankeu
    Fountzilas, Christos
    Li, Daneng
    Pelster, Meredith
    Liao, Chih-Yi
    Richards, Donald A.
    Deming, Dustin A.
    Younes, Mohamad Ahmad
    Mantry, Parvez
    Cohn, Allen Lee
    Kingsley, Ed
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Shan, Yujun
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 434 - 434
  • [49] Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxoliplatin in patients with advanced or metastatic solid tumours:: Results from a phase I study.
    Evans, J
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Baselga, J
    Bissett, D
    Regueiro, P
    Rubio, ED
    ANNALS OF ONCOLOGY, 2000, 11 : 51 - 51
  • [50] Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
    Arslan, Shukaib
    Fleming, Shaun
    Jain, Nitin
    Martinelli, Giovanni
    Stein, Anthony S.
    Blachly, James S.
    Bajel, Ashish
    Curti, Antonio
    Marconi, Giovanni
    Fabbri, Giulia
    Marmor, Yotvat
    Sharma, Shringi
    Elgeioushi, Nairouz
    Couto-Francisco, Natalia
    Saeh, Jamal
    Tibes, Raoul
    Cader, Fathima Zumla
    Konopleva, Marina
    BLOOD, 2022, 140 : 9091 - 9093
12345